<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20230830041022&amp;v=2.17.9.post6+86293ac&amp;utm_content=1 vU ePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc= 20230708114047&amp;utm_source = Chrome<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20230830041022&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 30 日星期三 08:10:22 +0000</lastbuilddate><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> DDM1 对组蛋白 H3 变体的染色质重塑是 DNA 甲基化表观遗传的基础</title><link/>https://pubmed.ncbi.nlm.nih.gov/37643610/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>核小体会阻止 DNA 甲基转移酶的进入，除非它们通过 DNA 甲基化 1 的减少 (DDM1^(LSH)^(^(/)HELLS)) 进行重塑，这是一种表观遗传遗传的类似 Snf2 的主调节因子。我们表明，DDM1 促进H3.1 产生组蛋白变体 H3.3。在 ddm1 突变体中，DNA 甲基化因 H3.3 伴侣 HIRA 的丢失而部分恢复，而 H3.1 伴侣 CAF-1 变得至关重要。单颗粒冷冻电镜结构3.2 Å 的 DDM1 与变异核小体揭示了...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 24 日：S0092-8674(23)00855-3. doi: 10.1016/j.cell.2023.08.001. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">核小体会阻止 DNA 甲基转移酶的进入，除非它们通过 DNA 甲基化 1 的减少 (DDM1 <sup>LSH</sup> <sup><sup>/</sup> HELLS</sup> ) 进行重塑，DNA 甲基化 1 是表观遗传的 Snf2 样主调节因子。我们表明，DDM1 促进组蛋白变体 H3.3 被 H3.1 取代在 ddm1 突变体中，DNA 甲基化因 H3.3 伴侣蛋白 HIRA 的丢失而部分恢复，而 H3.1 伴侣蛋白 CAF-1 变得至关重要。DDM1 3.2 Å 处的单颗粒冷冻电镜结构与变异核小体揭示了接合组蛋白 H3.3 靠近组装所需的残基以及未修饰的 H4 尾。N 端自抑制结构域抑制活性，而解旋酶结构域中的二硫键支持活性。DDM1 在组装过程中与 H3.1 和 H3.3 共定位细胞周期，以及 DNA 甲基转移酶 MET1 <sup>Dnmt1</sup> ，但被 H4K16 乙酰化阻断。雄性种系 H3.3 变体 MGH3/HTR10 对 DDM1 的重塑具有抵抗力，并充当精子细胞中表观遗传的占位核小体。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37643610/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37643610</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.001>10.1016/j.cell.2023.08.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37643610</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>李承祖</dc:creator><dc:creator>德克斯特·W·亚当斯</dc:creator><dc:creator>乔纳森·J·伊普萨罗</dc:creator><dc:creator>——乔纳森·卡恩</dc:creator><dc:creator>贾森·林恩</dc:creator><dc:creator>金贤秀</dc:creator><dc:creator>本杰明·贝鲁贝</dc:creator><dc:creator>维多利亚·梅杰</dc:creator><dc:creator>约瑟夫·P·卡拉科</dc:creator><dc:creator>尚塔尔·勒布朗</dc:creator><dc:creator>索娜莉·巴塔查吉</dc:creator><dc:creator>乌玛玛赫斯瓦里·拉穆</dc:creator><dc:creator>丹尼尔·格里马内利</dc:creator><dc:creator>雅尼克·雅各布</dc:creator><dc:creator>菲利普·沃伊特</dc:creator><dc:creator>利莫尔·约书亚·托尔</dc:creator><dc:creator>罗伯特·马丁森</dc:creator><dc:date>2023-08-29</dc:date><dc:source>细胞</dc:source><dc:title>DDM1 对组蛋白 H3 变体的染色质重塑是 DNA 甲基化表观遗传的基础</dc:title><dc:identifier>下午：37643610</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.001</dc:identifier></item><item><title>昼夜节律医学：心脏护理的关键策略</title><link/>https://pubmed.ncbi.nlm.nih.gov/37644115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol.2023 年 8 月 29 日。doi：10.1038/s41569-023-00925-8。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37644115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37644115</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00925-8>10.1038/s41569-023-00925-8</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37644115</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——迈克尔·J·索尔</dc:creator><dc:creator>塔米·马蒂诺</dc:creator><dc:date>2023-08-29</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>昼夜节律医学：心脏护理的关键策略</dc:title><dc:identifier>下午：37644115</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00925-8</dc:identifier></item><item><title>非甾体盐皮质激素受体拮抗剂治疗心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37644114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 8 月 29 日。doi：10.1038/s41569-023-00922-x。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37644114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37644114</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00922-x>10.1038/s41569-023-00922-x</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37644114</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>格拉西莫斯·菲利帕托斯</dc:creator><dc:creator>迪米特里奥斯·法马基斯</dc:creator><dc:date>2023-08-29</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>非甾体盐皮质激素受体拮抗剂治疗心力衰竭</dc:title><dc:identifier>下午：37644114</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00922-x</dc:identifier></item><item><title>开始使用盐皮质激素拮抗剂治疗射血分数降低的长期心力衰竭：迟做总比不做好？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 8 月 1 日：S0735-1097(23)06074-6。doi：10.1016/j.jacc.2023.06.022。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642609/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37642609</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.022>10.1016/j.jacc.2023.06.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642609</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——安德鲁·J·索尔</dc:creator><dc:creator>夏朱迪思</dc:creator><dc:date>2023-08-29</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>开始使用盐皮质激素拮抗剂治疗射血分数降低的长期心力衰竭：迟做总比不做好？</dc:title><dc:identifier>下午：37642609</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.022</dc:identifier></item><item><title>射血分数降低的心力衰竭患者盐皮质激素拮抗剂的利用不足</title><link/>https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>结论：长期 HFrEF 患者的临床状态较差，事件发生率较高，但无论 HFrEF 持续时间如何，依普利农的益处都是一致的。（NYHA II 级心力衰竭患者使用依普利酮或安慰剂治疗时的结果比较除了标准心力衰竭药物 [EMPHASIS-HF]；NCT00232180）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 8 月 1 日：S0735-1097(23)06073-4。doi：10.1016/j.jacc.2023.06.021。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：尚不清楚盐皮质激素受体拮抗剂的功效和安全性如何根据射血分数降低的心力衰竭（HFrEF）的持续时间而变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：在本研究中，我们试图根据 HFrEF 的持续时间评估依普利农的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在 EMPHASIS-HF 试验中，根据 HFrEF 持续时间创建 3 个患者组：&lt;1 年、1 至 &lt;5 年和≥5 年。主要结局是心力衰竭 (HF) 住院或心血管死亡的复合结果. 结果根据预先指定的预后变量进行调整，并使用 Cox 回归模型进行检查。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：每组患者人数分别为：975 例，&lt;1 岁；769 例，1 至&lt;5 岁；988 例，≥5 岁。长期心力衰竭患者年龄较大，更常见心血管和非心血管合并症。主要结局的比率（每 100 人年）随着 HFrEF 持续时间的增加而增加：&lt;1 年为 9.8 (95% CI: 8.4-11.4)，1 至 &lt;5 年为 13.5 (95% CI: 11.6-15.7)，17.6 (95% CI: 15.6-19.8) ≥5 年。依普利农的益处在整个 HF 持续时间内是一致的：主要结局的 HR 为 0.57 (95% CI: 0.42-0.79)，&lt;1 年为 0.81 (95% CI) : 0.60-1.10) 对于 1 至 &lt;5 年，和 0.61 (95% CI: 0.48-0.78) 对于 ≥ 5 年；P<sub>相互作用</sub>= 0.24。主要结局的治疗为 14 为 &lt;1 年，13 为 1 至 &lt; 5 年，持续时间≥5 年的为 10 年。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：长期 HFrEF 患者的临床状态较差，事件发生率较高，但无论 HFrEF 持续时间如何，依普利农的益处都是一致的。（NYHA II 级心力衰竭患者使用依普利酮或安慰剂治疗时的结果比较除了标准心力衰竭药物 [EMPHASIS-HF]；NCT00232180）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37642608</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.021>10.1016/j.jacc.2023.06.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642608</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>松本真吾</dc:creator><dc:creator>近藤彻</dc:creator><dc:creator>帕迪普·S·琼德</dc:creator><dc:creator>罗斯·T·坎贝尔</dc:creator><dc:creator>卡尔·斯韦德伯格</dc:creator><dc:creator>德克·J·范·维尔德豪森</dc:creator><dc:creator>斯图尔特·J·波科克</dc:creator><dc:creator>伯特伦·皮特</dc:creator><dc:creator>Faiez Zannad更多</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:date>2023-08-29</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>射血分数降低的心力衰竭患者盐皮质激素拮抗剂的利用不足</dc:title><dc:identifier>下午：37642608</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.021</dc:identifier></item><item><title> ESC 心血管再生和修复医学工作组</title><link/>https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 29 日：ehad538。doi：10.1093/eurheartj/ehad538。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37642557</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad538>10.1093/eurheartj/ehad538</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642557</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱利奥·庞皮利奥</dc:creator><dc:creator>里卡多·桑斯·鲁伊斯</dc:creator><dc:creator>约斯特 PG 斯鲁伊特</dc:creator><dc:creator>斯特凡·詹森斯</dc:creator><dc:date>2023-08-29</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>ESC 心血管再生和修复医学工作组</dc:title><dc:identifier>下午：37642557</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad538</dc:identifier></item><item><title>将商业广告的原则融入心血管健康促进工作中</title><link/>https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 29 日：ehad537。doi：10.1093/eurheartj/ehad537。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37642214/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37642214</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad537>10.1093/eurheartj/ehad537</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37642214</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>大卫·JT·坎贝尔</dc:creator><dc:creator>Raj Pannu更多</dc:creator><dc:creator>布雷登·J·曼斯</dc:creator><dc:date>2023-08-29</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>将商业广告的原则融入心血管健康促进工作中</dc:title><dc:identifier>下午：37642214</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad537</dc:identifier></item><item><title> S14-磷酸化 RPN6 通过 PKA 介导蛋白酶体激活并减轻蛋白病</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>结论：本研究在动物中证实 pS14-Rpn6 通过 PKA 介导 26S 蛋白酶体的激活，并且减少的 pS14-Rpn6 是心脏蛋白病的关键致病因素，从而确定了减少心脏蛋白毒性的新治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.322887。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：更好地了解蛋白酶体活性的调节有助于寻找新的治疗策略。细胞培养研究表明，cAMP依赖性PKA（蛋白激酶A）通过pS14-Rpn6（丝氨酸14磷酸化Rpn6）激活26S蛋白酶体，但这一发现及其生理意义仍有待在体内确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：创建 Rpn6 Ser14 突变为 Ala (S14A [Rpn6/Psmd11 <sup>S14A</sup> ]) 或 Asp (S14D) 的雄性和雌性小鼠，分别阻断或模拟 pS14-Rpn6，并与源自它们的细胞一起使用。泛素-蛋白酶体系统功能通过 GFPdgn 报告小鼠和蛋白酶体活性测定进行评估。在过度表达错误折叠蛋白 R120G-CryAB (R120G) 的小鼠和心肌细胞中测试了 S14A 和 S14D 对蛋白毒性的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：PKA 激活增加了野生型而非 S14A 胚胎成纤维细胞（小鼠胚胎成纤维细胞）、成年心肌细胞和小鼠心脏中的 pS14-Rpn6 和 26S 蛋白酶体活性。S14D 心肌和成年小鼠心肌细胞中的基础 26S 蛋白酶体活性显着高于对照组。与野生型对应物相比，S14D::GFPdgn 小鼠显示出比 GFPdgn 小鼠更低的心肌 GFPdgn 蛋白，但不显示 mRNA 水平。在 R120G 小鼠（心脏蛋白毒性的经典模型）中，与非转基因同窝小鼠相比，基础心肌 pS14-Rpn6 显着降低。与野生型新生儿心肌细胞相比，S14D 新生心肌细胞对 R120G 的蛋白酶体降解速度显着加快。与 R120G 小鼠相比，S14D/S14D::R120G 小鼠的心肌蛋白酶体活性显着增强，总泛素和 K48 连接泛素缀合物以及异常泛素缀合物水平较低。 CryAB蛋白聚集，胎儿基因再激活减少，心脏肥大，心脏功能障碍延迟。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：本研究在动物中证实 pS14-Rpn6 通过 PKA 介导 26S 蛋白酶体的激活，并且减少的 pS14-Rpn6 是心脏蛋白病的关键致病因素，从而确定了减少心脏蛋白毒性的新治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37641975</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322887>10.1161/CIRCRESAHA.123.322887</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641975</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>杨柳青</dc:creator><dc:creator>尼尔玛·帕拉茹利</dc:creator><dc:creator>吴鹏龙</dc:creator><dc:creator>刘金宝</dc:creator><dc:creator>王学军更多</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>S14-磷酸化 RPN6 通过 PKA 介导蛋白酶体激活并减轻蛋白病</dc:title><dc:identifier>下午：37641975</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322887</dc:identifier></item><item><title>罕见变异遗传学和扩张型心肌病严重程度：DCM 精准医学研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>结论：与较不严重的 DCM 个体相比，晚期 DCM 与被判定为致病性或可能致病性的 DCM 基因中罕见变异的几率较高相关。这一发现可能有助于评估 DCM 患者及其高危患者管理中的结果风险。家庭成员。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 29 日。doi：10.1161/CIRCULATIONAHA.123.064847。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：扩张型心肌病 (DCM) 可导致晚期疾病，本文定义为需要耐用的左心室辅助装置或心脏移植 (LVAD/HT)。已知 DCM 具有遗传基础，但罕见变异遗传学与高级DCM尚未研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们分析了 2016 年至 2021 年美国多中心 DCM 精准医学研究中入组患者的临床和基因序列数据，该研究是一个地域多样、多种族、多民族的队列。临床评估包括标准化患者访谈和病历查询表。DCM 严重程度被分为 3 组：患有 LVAD/HT 的晚期疾病患者；仅植入式心律转复除颤器 (ICD) 的患者；或无 ICD 或 LVAD/HT 的患者。36 个 DCM 基因中的罕见变异被分类为致病性或可能致病性或我们考虑的混杂因素包括人口特征、生活方式因素、获得护理的机会、DCM 持续时间和合并症。使用具有广义 Logit 关联的多项模型评估 DCM 严重程度与罕见变异遗传结果之间的粗略和调整关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者的平均 (SD) 年龄为 51.9 (13.6) 岁；42% 为非洲血统，56% 为欧洲血统，44% 为女性。1198 名患者中，347 名患有 LVAD/HT，511 名患有 ICD对于 LVAD/HT、仅 ICD 或两者都没有的患者，具有致病性或可能致病性变异的患者比例分别为 26.2%、15.9% 和 15.0%。那些没有 LVAD/HT 或 ICD 的患者具有与 DCM 相关的致病性或可能致病性罕见变异（比值比，2.3 [95% CI，1.5–3.6]）。相关性并没有因血统而异。罕见变异的遗传发现在患有 DCM 的患者之间相似。带 ICD 的 DCM 和不带 LVAD/HT 或 ICD 的 DCM。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与较不严重的 DCM 个体相比，晚期 DCM 与被判定为致病性或可能致病性的 DCM 基因中罕见变异的几率较高相关。这一发现可能有助于评估 DCM 患者及其高危患者管理中的结果风险。家庭成员。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT03037632。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37641966</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064847>10.1161 / CIRCULATIONAHA.123.064847</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641966</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>马克·霍夫迈尔</dc:creator><dc:creator>加里·J·哈斯</dc:creator><dc:creator>伊丽莎白乔丹</dc:creator><dc:creator>曹金文</dc:creator><dc:creator>埃文·克兰斯多夫</dc:creator><dc:creator>——格雷戈里·A·埃瓦尔德</dc:creator><dc:creator>阿兰娜·莫里斯</dc:creator><dc:creator>安贾利·欧文斯</dc:creator><dc:creator>布赖恩·洛斯</dc:creator><dc:creator>道格拉斯·斯托勒</dc:creator><dc:creator>WH 邓伟逊</dc:creator><dc:creator>索尼娅·加尔格</dc:creator><dc:creator>巴里·特拉亨伯格</dc:creator><dc:creator>帕拉克·沙阿</dc:creator><dc:creator>萨尔皮 V 庞布基安</dc:creator><dc:creator>南希·K·斯威策</dc:creator><dc:creator>——马修·T·惠勒</dc:creator><dc:creator>简·E·威尔科克斯</dc:creator><dc:creator>——斯图尔特·卡茨</dc:creator><dc:creator>斯蒂芬·潘</dc:creator><dc:creator>哈维尔希门尼斯</dc:creator><dc:creator>弗兰克·斯马特</dc:creator><dc:creator>——王杰西卡</dc:creator><dc:creator>斯蒂芬·戈特利布</dc:creator><dc:creator>丹尼尔·P·贾奇</dc:creator><dc:creator>查尔斯·K·摩尔</dc:creator><dc:creator>——戈登·S·哈金斯</dc:creator><dc:creator>丹尼尔·D·金纳蒙</dc:creator><dc:creator>倪瀚宇</dc:creator><dc:creator>雷·E·赫什伯格</dc:creator><dc:creator>DCM联盟的DCM精准医学研究</dc:creator><dc:date>2023-08-29</dc:date><dc:source>循环</dc:source><dc:title>罕见变异遗传学和扩张型心肌病严重程度：DCM 精准医学研究</dc:title><dc:identifier>下午：37641966</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064847</dc:identifier></item><item><title>运动期间心脏迷走神经活动增加，以增强冠状动脉血流量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>结论：我们的研究表明，心脏迷走神经活动实际上会增加，对于运动期间维持心脏功能至关重要。此外，我们的研究结果表明，运动期间冠状动脉血流的动态调节是由 VIP 介导的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.323017。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在讨论运动过程中心脏的自主控制时，经常使用“迷走神经完全撤退”这个词。然而，最近的研究对这一假设提出了挑战。我们假设心脏迷走神经活动在运动过程中增加，并通过乙酰胆碱以外的递质维持心脏功能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对清醒的成年羊进行全身跑步机运动时，长期直接记录心脏迷走神经活动、心输出量、冠状动脉血流量和心率。用亲脂性示踪染料证实左心迷走神经分支的心脏神经支配。 DiO）。用乙酰胆碱药物阻断剂（阿托品，250 mg）、VIP（血管活性肠肽；[4Cl-D-Phe6，Leu17] VIP 25 µg）或盐水对照对绵羊进行锻炼，在不同的日子随机进行。左心脏迷走神经分支被去神经支配。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在主要心脏神经节丛以及与冠状动脉相关的脂肪垫内可以看到来自心脏迷走神经分支的神经支配。直接记录的心脏迷走神经活动在运动期间增加。左心脏迷走神经分支去神经减弱了冠状动脉的最大变化血流量（最大运动，对照：63.5±5.9 mL/min，n=8；心脏迷走神经去神经：32.7±5.6 mL/min，n=6， <i>P=</i> 2.5×10 <sup>-</sup> <sup>7</sup> ）、心输出量和心率阿托品不会影响运动期间的任何心脏参数，但 VIP 拮抗作用显着降低运动期间的冠状动脉血流量，达到与迷走神经去神经术相似的水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究表明，心脏迷走神经活动实际上会增加，对于运动期间维持心脏功能至关重要。此外，我们的研究结果表明，运动期间冠状动脉血流的动态调节是由 VIP 介导的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37641938</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323017>10.1161/CIRCRESAHA.123.323017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641938</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱莉娅·香克斯</dc:creator><dc:creator>姆里杜拉·帕钦</dc:creator><dc:creator>张伟华</dc:creator><dc:creator>宾杜·乔治更多</dc:creator><dc:creator>罗希特·拉姆钱德拉</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>运动期间心脏迷走神经活动增加，以增强冠状动脉血流量</dc:title><dc:identifier>下午：37641938</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323017</dc:identifier></item><item><title>中性粒细胞血运重建需要 TNFα 激活 CCR6 和 CCL20</title><link/> https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>结论：我们证明，通过 TNFα 对 CCL20-CCR6 轴进行位点特异性激活，可将表达促血管生成 VEGFA 的中性粒细胞募集到缺血性损伤部位，从而启动肌肉组织血运重建。这些发现为组织血运重建提供了一个有吸引力的选择，特别是在糖尿病条件下。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 29 日。doi：10.1161/CIRCRESAHA.123.323071。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：涉及 TNFα（肿瘤坏死因子 α）信号传导的免疫炎症途径的激活对于缺血性损伤后的血运重建和外周肌肉组织修复至关重要。尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过激光多普勒成像和光片荧光显微镜监测突变小鼠永久股动脉结扎后的肌肉组织血运重建。TNFα介导的信号传导和CCL20（CC基序趋化因子配体20）-CCR6（CC趋化因子受体6）的作用使用骨髓移植、流式细胞术以及生化和分子生物学技术在体外和体内研究了新血管形成的轴。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：发现TNFα介导的肿瘤坏死因子受体TNFR（肿瘤坏死因子受体）1而非TNFR2的激活是缺血后肌肉组织血运重建所必需的。骨髓来源的CCR6 <sup>+</sup>中性粒细胞被鉴定为先前未描述的TNFα诱导的促血管生成中性粒细胞群，其特征是 VEGFA（血管内皮生长因子 A）表达增加。表达 VEGFA 的促血管生成中性粒细胞依赖 CCL20 募集到缺血部位。改善糖尿病缺血骨骼肌的血运重建，通过氟伐他汀序贯治疗得以维持。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们证明，通过 TNFα 对 CCL20-CCR6 轴进行位点特异性激活，可将表达促血管生成 VEGFA 的中性粒细胞募集到缺血性损伤部位，从而启动肌肉组织血运重建。这些发现为组织血运重建提供了一个有吸引力的选择，特别是在糖尿病条件下。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37641931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37641931</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323071>10.1161/CIRCRESAHA.123.323071</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37641931</guid><pubDate> Tue, 29 Aug 2023 06:00:00 -0400</pubDate><dc:creator>霍尔格·洛希纳</dc:creator><dc:creator>莱娅·卡内斯·埃斯特夫</dc:creator><dc:creator>玛丽亚·埃莉莎去</dc:creator><dc:creator>罗克珊·哈泽内特</dc:creator><dc:creator>娜塔莉·布拉克曼</dc:creator><dc:creator>普拉文·加贾瓦达</dc:creator><dc:creator>斯特凡·冈瑟</dc:creator><dc:creator>尼古拉斯·多尔</dc:creator><dc:creator>约亨·珀林</dc:creator><dc:creator>托马斯·布劳恩</dc:creator><dc:date>2023-08-29</dc:date><dc:source>流通研究</dc:source><dc:title>中性粒细胞血运重建需要 TNFα 激活 CCR6 和 CCL20</dc:title><dc:identifier>下午：37641931</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323071</dc:identifier></item><item><title>降脂治疗后冠状动脉粥样硬化的消退和稳定</title><link/>https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>结论：三分之一接受高强度降脂治疗的 AMI 患者出现三重回归，并且与 alirocumab 治疗、较高的基线脂质含量和减少的心血管事件相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 20 日：S0735-1097(23)06468-9。doi：10.1016/j.jacc.2023.08.019。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：接受高强度降脂治疗并同时出现粥样斑块体积减少、脂质含量减少和纤维帽厚度增加（即“三重回归”）的患者的频率、特征和结果尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在调查急性心肌梗死 (AMI) 并接受高强度降脂治疗的患者三重回归的发生率、决定因素和预后影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：PACMAN-AMI 试验采用连续血管内超声、近红外光谱和光学相干断层扫描来比较 alirocumab 与安慰剂在接受高强度他汀类药物治疗的患者中的效果。三重回归是通过动脉粥样硬化百分比的组合存在来定义的体积 (PAV) 减少、最大脂质核心负荷指数 4 毫米以内 (maxLCBI <sub>4mm</sub> ) 减少、最小纤维帽厚度 (FCT) 增加。评估一年随访时的临床结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总体而言，84 名患者 (31.7%) 出现三重回归（alirocumab 组为 40.8%，安慰剂组为 23.0%，p=0.002）。无三重回归（组间差异 -27.1 [-37.7 至 -16.6] mg/dl，p&lt;0.001）。三重回归由 alirocumab 治疗独立预测（比值比 [OR] 2.83，95% 置信区间 [CI] 1.57-5.16，p=0.001）和更高的基线 maxLCBI <sub>4 mm</sub> （OR 1.03，95%CI 1.01-1.06，p=0.013）。与没有三重回归的情况相比（8.3% 与 18.2%，p=0.04）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：三分之一接受高强度降脂治疗的 AMI 患者出现三重回归，并且与 alirocumab 治疗、较高的基线脂质含量和减少的心血管事件相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37640248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37640248</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.019>10.1016/j.jacc.2023.08.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37640248</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗拉维奥·G·比西雷</dc:creator><dc:creator>乔纳斯·汉纳</dc:creator><dc:creator>西尔万·洛斯达特</dc:creator><dc:creator>植木靖</dc:creator><dc:creator>涉谷弘树</dc:creator><dc:creator>大冢达彦</dc:creator><dc:creator>柿崎良太</dc:creator><dc:creator>托马斯·霍夫鲍尔</dc:creator><dc:creator>罗伯特·扬·范格恩斯</dc:creator><dc:creator>斯特凡·斯托特基</dc:creator><dc:creator>乔治斯·西昂蒂斯</dc:creator><dc:creator>莎拉·巴尔</dc:creator><dc:creator>雅各布·伦伯格</dc:creator><dc:creator>迪克·赫格</dc:creator><dc:creator>克里斯托夫·凯撒</dc:creator><dc:creator>大卫·斯皮克</dc:creator><dc:creator>乔斯特·戴门</dc:creator><dc:creator>胡安·伊格莱西亚斯</dc:creator><dc:creator>史蒂芬·温德克</dc:creator><dc:creator>托马斯·恩斯特罗姆</dc:creator><dc:creator>艾琳·朗</dc:creator><dc:creator>康斯坦丁诺斯·C·科斯基纳斯</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:date>2023-08-28</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>降脂治疗后冠状动脉粥样硬化的消退和稳定</dc:title><dc:identifier>下午：37640248</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.019</dc:identifier></item><item><title>什么是正常左心室射血分数？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):750-752. doi: 10.1161/CIRCULATIONAHA.123.065791. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639509</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065791>10.1161 / CIRCULATIONAHA.123.065791</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639509</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>保罗·海登赖希</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>什么是正常左心室射血分数？</dc:title><dc:identifier>下午：37639509</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065791</dc:identifier></item><item><title> Ostadal 和 Belohlavek 对有关文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):804.doi: 10.1161/CIRCULATIONAHA.123.065358. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639508</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065358>10.1161/CIRCULATIONAHA.123.065358</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639508</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>彼得·奥斯塔达尔更多</dc:creator><dc:creator>扬·贝洛拉维克</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>Ostadal 和 Belohlavek 对有关文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信件的回应</dc:title><dc:identifier>下午：37639508</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065358</dc:identifier></item><item><title> Ferreira 关于文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):803. doi: 10.1161/CIRCULATIONAHA.122.063622. Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639506</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063622>10.1161/CIRCULATIONAHA.122.063622</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639506</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator>豪尔赫·费雷拉</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>Ferreira 关于文章“心源性休克治疗中的体外膜氧合：ECMO-CS 随机临床试验的结果”的信函</dc:title><dc:identifier>下午：37639506</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063622</dc:identifier></item><item><title>消除医学中结构性种族主义的阶段：关注医学培训</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 8 月 29 日；148(9):800-802.doi: 10.1161/CIRCULATIONAHA.123.066131. ​​Epub 2023 年 8 月 28 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37639505/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639505</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066131>10.1161 / CIRCULATIONAHA.123.066131</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37639505</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Nisha Donthi更多</dc:creator><dc:creator>凯瑟琳·R·露西</dc:creator><dc:creator>米歇尔·阿尔伯特</dc:creator><dc:date>2023-08-28</dc:date><dc:source>循环</dc:source><dc:title>消除医学中结构性种族主义的阶段：关注医学培训</dc:title><dc:identifier>下午：37639505</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066131</dc:identifier></item><item><title>高收入、中等收入和低收入国家心力衰竭患者的虚弱和结局</title><link/>https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230830041022&amp;v=2.17.9.post6+86293ac<description>结论：虚弱为预测死亡和心衰住院的预后变量提供了大量增量预后信息。虚弱与这些结果之间的关系在所有收入水平的国家中都是一致的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 28 日：ehad595。doi：10.1093/eurheartj/ehad595。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：除了来自不同国家收入水平的心力衰竭（HF）人群的传统预后变量之外，关于衰弱的增量预后重要性的信息很少。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: 3429 adults with HF (age 61±14 years, 33% women) from 27 high-, middle- and low-income countries were prospectively studied. Baseline frailty was evaluated by the Fried index, incorporating handgrip strength, gait speed, physical activity, unintended weight loss and self-reported exhaustion. Mean left ventricular ejection fraction was 39±14% and 26% had New York Heart Association (NYHA) class III/IV symptoms. Participants were followed for a median (25th-75th percentile) 3.1 (2.0-4.3) years. Cox proportional hazards models for death and HF hospitalization adjusted for country income level; age; sex; education; HF etiology; left ventricular ejection fraction; diabetes; tobacco and alcohol use; NYHA functional class; HF medication use; blood pressure; hemoglobin, sodium and creatinine concentrations were performed. The incremental discriminatory value of frailty over and above the MAGGIC risk score was evaluated by the area under the receiver-operating characteristic curve. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: At baseline, 18% of participants were robust, 61% pre-frail and 21% frail. During follow-up, 565 (16%) participants died and 471 (14%) were hospitalized for HF. Respective adjusted hazard ratios [HRs (95% CI)] for death among the prefrail and frail were 1.59 (1.12-2.26) and 2.92 (1.99-4.27). Respective adjusted HRs (95% CI) for HF hospitalization were 1.32 (0.93-1.87) and 1.97 (1.33-2.91). Findings were consistent among different country income levels and by most subgroups. Adding frailty to the MAGGIC risk score improved the discrimination of future death and HF hospitalization. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639487</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad595>10.1093/eurheartj/ehad595</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639487</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Darryl P Leong</dc:creator><dc:creator> Philip Joseph</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:creator> Jean Rouleau</dc:creator><dc:creator> Aldo P Maggioni</dc:creator><dc:creator> Fernando Lanas</dc:creator><dc:creator> Sanjib K Sharma</dc:creator><dc:creator> Julio Núñez</dc:creator><dc:creator> Bishav Mohan</dc:creator><dc:creator> Ahmet Celik</dc:creator><dc:creator> Jabir Abdullakutty</dc:creator><dc:creator> Okechukwu S Ogah</dc:creator><dc:creator> Lisa M Mielniczuk</dc:creator><dc:creator> Kumar Balasubramanian</dc:creator><dc:creator> Tara McCready</dc:creator><dc:creator> Alex Grinvalds</dc:creator><dc:creator> Salim Yusuf</dc:creator><dc:creator> P Joseph</dc:creator><dc:creator> G-CHF Investigators</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries</dc:title><dc:identifier> pmid:37639487</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad595</dc:identifier></item><item><title> Third generation PCSK9-Inhibitors</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830041022&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad566. doi: 10.1093/eurheartj/ehad566. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639486</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad566>10.1093/eurheartj/ehad566</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639486</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Ulrich Laufs</dc:creator><dc:creator> Matthias Blüher</dc:creator><dc:creator> Berend Isermann</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Third generation PCSK9-Inhibitors</dc:title><dc:identifier> pmid:37639486</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad566</dc:identifier></item><item><title> Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830041022&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093/eurheartj/ehad561. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Emery-Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants also cause end-stage heart failure (ESHF) and malignant ventricular arrhythmia (MVA). This study aimed to better characterise the cardiac complications of EMD variants. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Consecutively referred EMD variant-carriers were retrospectively recruited from 12 international cardiomyopathy units. MVA and ESHF incidence in male and female variant-carriers was determined. Male EMD variant-carriers with a cardiac phenotype at baseline (EMDCARDIAC) were compared to consecutively recruited male LMNA variant-carriers with a cardiac phenotype at baseline (LMNACARDIAC). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Longitudinal follow-up data were available for 38 male and 21 female EMD variant-carriers (mean [SD] ages 33.4 [13.3] and 43.3 [16.8] years, respectively). Nine (23.6%) males developed MVA and five (13.2%) developed ESHF during a median [IQR] follow-up of 65.0 [24.3, 109.5] months. No female EMD variant-carrier had MVA or ESHF, but nine (42.8%) developed a cardiac phenotype at a median [IQR] age of 58.6 [53.2, 60.4] years. Incidence rates for MVA were similar for EMDCARDIAC and LMNACARDIAC (4.8 and 6.6 per 100 person-years, respectively; log-rank p = 0.49). Incidence rates for ESHF were 2.4 and 5.9 per 100 person-years for EMDCARDIAC and LMNACARDIAC, respectively (log-rank p = 0.09). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Male EMD variant-carriers have a risk of progressive heart failure and ventricular arrhythmias similar to that of male LMNA variant-carriers. Early implantable cardioverter defibrillator implantation and heart failure drug therapy should be considered in male EMD variant-carriers with cardiac disease.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639473</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad561>10.1093/eurheartj/ehad561</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639473</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Douglas E Cannie</dc:creator><dc:creator> Petros Syrris</dc:creator><dc:creator> Alexandros Protonotarios</dc:creator><dc:creator> Athanasios Bakalakos</dc:creator><dc:creator> Jean-François Pruny</dc:creator><dc:creator> Raffaello Ditaranto</dc:creator><dc:creator> Cristina Martinez-Veira</dc:creator><dc:creator> Jose M Larrañaga-Moreira</dc:creator><dc:creator> Kristen Medo</dc:creator><dc:creator> Francisco José Bermúdez-Jiménez</dc:creator><dc:creator> Rabah Ben Yaou</dc:creator><dc:creator> France Leturq</dc:creator><dc:creator> Ainhoa Robles Mezcua</dc:creator><dc:creator> Chiara Marini-Bettolo</dc:creator><dc:creator> Eva Cabrera</dc:creator><dc:creator> Chloe Reuter</dc:creator><dc:creator> Javier Limeres Freire</dc:creator><dc:creator> José F Rodríguez-Palomares</dc:creator><dc:creator> Luisa Mestroni</dc:creator><dc:creator> Matthew RG Taylor</dc:creator><dc:creator> Victoria N Parikh</dc:creator><dc:creator> Euan A Ashley</dc:creator><dc:creator> Roberto Barriales-Villa</dc:creator><dc:creator> Juan Jiménez-Jáimez</dc:creator><dc:creator> Pablo Garcia-Pavia</dc:creator><dc:creator> Philippe Charron</dc:creator><dc:creator> Elena Biagini</dc:creator><dc:creator> José M García Pinilla</dc:creator><dc:creator> John Bourke</dc:creator><dc:creator> Konstantinos Savvatis</dc:creator><dc:creator> Karim Wahbi</dc:creator><dc:creator> Perry M Elliott</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure</dc:title><dc:identifier> pmid:37639473</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad561</dc:identifier></item><item><title> Frailty: A new Vital Sign in Heart Failure Comes of age</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830041022&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093/eurheartj/ehad559. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639470</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad559>10.1093/eurheartj/ehad559</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639470</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Finlay A McAlister</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Frailty: A new Vital Sign in Heart Failure Comes of age</dc:title><dc:identifier> pmid:37639470</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad559</dc:identifier></item><item><title> Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230830041022&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 28:ehad596. doi: 10.1093/eurheartj/ehad596. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Lerodalcibep, a novel small recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin demonstrated highly effective low-density lipoprotein cholesterol (LDL-C) reduction with monthly 300 mg in 1.2 ml SC dosing in Phase 2. In this global Phase 3 trial, the safety and efficacy of lerodalcibep was evaluated in heterozygous familial hypercholesterolaemia (HeFH) patients requiring additional LDL-C lowering. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients were randomized 2:1 to monthly SC injections of either lerodalcibep 300 mg or placebo for 24 weeks. The primary efficacy endpoints were the percent change from baseline in LDL-C at Week 24 and the mean of Weeks 22 and 24. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In 478 randomized subjects [mean age (range); 53 (18-80) years, 51.7% female, mean (SD) baseline LDL-C 3.88 (1.66) mmol/L] lerodalcibep reduced LDL-C, compared to placebo by an absolute amount of 2.08 (0.11) mmol/L [LS mean(SE); 95% CI -2.30 to -1.87] with a percentage difference of -58.61 (3.25)% at Week 24 and by 2.28 (0.10) mmol/L (95% CI -2.47 to -2.09) with a percentage difference of -65.0 (2.87)% at the mean of Weeks 22 and 24 (P &lt; 0.0001 for all). With lerodalcibep, 68% of subjects achieved both a reduction in LDL-C ≥ 50% and the recommended ESC LDL-C targets during the study. Except for mild injection site reactions, treatment-emergent adverse events were similar between lerodalcibep and placebo. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37639462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230830041022&v=2.17.9.post6+86293ac">37639462</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad596>10.1093/eurheartj/ehad596</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37639462</guid><pubDate> Mon, 28 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Frederick Raal</dc:creator><dc:creator> Nyda Fourie</dc:creator><dc:creator> Russell Scott</dc:creator><dc:creator> Dirk Blom</dc:creator><dc:creator> Matthys De Vries Basson</dc:creator><dc:creator> Meral Kayikcioglu</dc:creator><dc:creator> Kate Caldwell</dc:creator><dc:creator> David Kallend</dc:creator><dc:creator> Evan Stein</dc:creator><dc:creator> LIBerate-HeFH Investigators</dc:creator><dc:date> 2023-08-28</dc:date><dc:source> European heart journal</dc:source><dc:title> Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial</dc:title><dc:identifier> pmid:37639462</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad596</dc:identifier></item></channel></rss>